Reviewer's report

Title: Dose and aging effect on patients reported treatment benefit switching the first Overactive Bladder therapy with Tolterodine ER to Fesoterodine: Post-hoc analysis from an observational and retrospective study

Version: 1 Date: 30 March 2012

Reviewer: alayne markland

Reviewer's report:

This is a well-written manuscript supported by Pfizer, Inc. Europe that adds supportive data showing that age was not a factor in treatment benefit from switching from Tolteradine ER to Fesoterodine. Dosage (4 mg or 8 mg) did appear to be a factor in patient and physician treatment benefit statistically, although this benefit is questionable for any clinical benefit with possible ceiling effects seen (improvement from 91% to 96% on the CGI-I, p=0.004). A few minor comments below by section may need to be addressed prior to publication.

Comments by section:

Abstract: Please include methods section in abstract. Revise statement in results and conclusion sections, “improvements were mostly not affected by age.” The improvements were not affected by age.

Introduction: No further comments.

Methods: Please include methodology section after the introduction. Revise what is meant by “HTA” and “ictus.”

Results:

Table 1 – please clarify what is meant by “OAB evolution time,” “HTA”, and “ictus.”

Tables 3 and 4 – values are not represented by mean values and 95% CI. For tables 3 and 4, Mean values and standard deviation or 95% CI are needed. For the reader, including p values comparing the two groups in the table would be helpful. Reporting the F statistic and the correlation coefficient is not helpful. Please report this for both Tables 3 and 4.

Discussion:

Please comment on the ceiling effects seen in the different subgroup analyses – age and dose.

Acknowledgements:

Should Esther Tapia be an author for drafting the manuscript?

Level of interest: An article whose findings are important to those with closely related research interests
Quality of written English: Needs some language corrections before being published

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests: I declare that I have no competing interests